Xstim receives FDA premarket application approval of spine fusion stimulator
Click Here to Manage Email Alerts
Key takeaways:
- Xstim Inc. received FDA premarket application approval of its Xstim spine fusion stimulator.
- The device is designed to promote bone healing after spinal fusion surgery.
Xstim Inc. announced it received FDA premarket application approval of its Xstim spine fusion stimulator to promote bone healing after spinal fusion surgery, according to a company press release.
The Xstim device is a non-invasive bone growth stimulator for patients to use during therapy after spinal fusion surgery, according to the release.
“Xstim Inc. is dedicated to empowering patients and surgeons to elevate the quality of care in spinal fusion rehabilitation,” Jeremy Perkins, CEO of Xstim Inc., said in the release. “The introduction of the Xstim spine fusion stimulator represents the beginning of our robust pipeline of bone growth stimulation innovations. We are poised to collaborate with health care providers and distribution partners to enhance bone fusion outcomes and elevate patient satisfaction. This FDA approval underscores our leadership in and dedication to the bone growth stimulation market.”
The Xstim device will be commercially available in the second quarter of 2024, according to the release.
Read more about
Click Here to Manage Email Alerts